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LIST OF ABREVIATIONS 
ACQ = Asthma Control Questionnaire 
ADIS-IV = Anxiety Disorders Interview Schedule for DSM-IV 
BMI = Body Mass Index 
CO2 = Carbon Dioxide 
DBP = Diastolic Blood Pressure 
DSM-IV-TR = Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revised 
DSM-5 = Diagnostic and Statistical Manual of Mental Disorders, 5th edition 
FEV1 = Forced Expiratory Volume in one second 
FVC = Forced Vital Capacity 
GLM = General Linear Model 
HR = Heart Rate 
ICS = Inhaled Corticosteroid 
MCT = Methacholine Challenge Test 
PA = Panic Attack 
PC20 = Provocative Concentration of methacholine 
PD = Panic Disorder 
PSS = Panic Symptom Scale 
RR = Respiratory Rate 
SBP = Systolic Blood Pressure 
SD-VAS = Subjective Distress Visual Analogue Scale 
VCO2 = Carbon Dioxide Production 
VE = Minute Ventilation 
VO2 = Oxygen Uptake 
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VT = Tidal Volume  
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ABSTRACT 
Background: Panic disorder (PD) is common among asthmatics and is associated with worse 
asthma outcomes. This may occur due to psychophysiological factors or to cognitive/affective 
factors. This study evaluated the impact of panic attacks (PAs) on bronchoconstriction and 
subjective distress in asthmatics with and without PD. Methods: A total of 25 asthmatics (15 
with PD who had a PA [PD/PA], 10 without PD who didn’t have a PA [noPD/noPA]) were 
recruited from an outpatient clinic. They underwent a panic challenge (one vital capacity 
inhalation of 35% carbon dioxide [CO2]) and completed the Panic Symptom Scale (PSS), the 
Subjective Distress Visual Analogue Scale (SD-VAS) and the Borg Scale before and after CO2. 
Forced expiratory volume in one second (FEV1) was assessed pre and post CO2; respiratory (i.e., 
CO2 production [VCO2], minute ventilation [VE], tidal volume [VT]) were continuously 
recorded, and physiological measures (i.e., systolic and diastolic blood pressure [SBP/DBP]), 
every two minutes. Results: Analyses adjusting for age, sex, and provocative concentration of 
methacholine revealed no significant differences between groups in FEV1 change after CO2 
inhalation (F(1,23)<0.01, p=.961). However, PD/PA patients reported more panic 
(F(1,22)=18.10, p<.001), anxiety (F(1,22)=21.93, p<.001), worry (F(1,22)=26.31, p<.001) and 
dyspnea (F(1,22)=4.68, p=.042), and exhibited higher levels of VCO2 (F(1,2843)=5.89, p=.015), 
VE (F(1,2844)=4.48, p=.034), and VT (F(1,2844)=4.62, p=.032) after the CO2 challenge, 
compared to noPD/noPA patients. Conclusions: Results, presented as hypothesis generating, 
suggest that asthmatics with PD/PA exhibit increased panic-like anxiety, breathlessness and a 
respiratory pattern consistent with hyperventilation that was not linked to statistically significant 
drops in bronchoconstriction.  
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INTRODUCTION 
During the last decade, studies have observed a high prevalence of anxiety disorders in 
asthma populations, with a point prevalence of up to 34% in adults (1). Panic disorder (PD) has 
been shown to be the most prevalent anxiety disorder in individuals with asthma, with rates 
ranging from 6.5-24%, which is up to 10 times the rate observed in the general population (1-5). 
PD is characterized by sudden, recurrent panic attacks (PAs), which are episodes of intense fear 
or discomfort associated with at least four cognitive (e.g., fear of losing control, fear of dying) 
and/or physiological (e.g., shortness of breath, dizziness, chest tightness) symptoms (6). PD has 
also been associated with worse asthma outcomes, including increased physician visits, 
emergency visits, rescue medication use, and reduced asthma-related quality of life (7-9). The 
link between PD and worse asthma outcomes is quite robust and, although the mechanisms 
remain poorly understood, PAs may be the pathway through which they are linked.  
Several theories have been developed to explain the relationship between asthma and PD 
and how this comorbidity may lead to worse asthma outcomes. In general, these theories may be 
categorized as “psychophysiological” or “cognitive/affective”. The “psychophysiological” theory 
postulates that PD leads to worse asthma outcomes through direct physiological pathways, 
notably via anxiety (specifically panic)-induced increases in autonomic arousal leading to 
increased parasympathetic drive, resulting in bronchial hyper-responsiveness and obstruction (10, 
11). For example, a study from Hibbert and colleagues (1988) monitored transcutaneous PCO2 in 
patients with asthma and found that hyperventilation precedes exacerbation of asthma, which 
suggests that panic may trigger an asthma attack through hyperventilation and airway cooling. In 
contrast, the “cognitive/affective” theory postulates that PD leads to worse asthma outcomes due 
to a tendency to misattribute panic-related anxiety symptoms as asthma symptoms and/or to 
catastrophize symptoms of breathlessness that signal a possible “asthma” attack (12, 13). This 
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may result in increased rescue medication use and health care seeking in the absence of true 
airway obstruction (7). For example, a study from Van Peski-Oosterbaan and colleagues (1996) 
found no differences in pulmonary function in patients with asthma and with (and without) PD 
during induced bronchoconstriction, but found that PD patients reported higher levels of 
breathlessness, which could be due to catastrophisation. Asthma attacks and PAs share several 
overlapping symptoms, such as shortness of breath, sensations of being smothered, choking, and 
heightened anxiety (including fears of suffocating/dying). This symptom overlap, and possible 
symptom confusion (12), may also influence asthma outcomes (7, 8).  
Though previous studies have found evidence supporting both theories (2, 10, 12), results 
have been inconclusive and no studies to date have directly assessed the impact of PAs on both 
objective airway obstruction and subjective responses in documented asthmatics with PD. One of 
the most reliable ways to induce a PA in a laboratory setting is through carbon dioxide (CO2) 
inhalation, which has been shown to be both safe and non-invasive (12). A recent systematic 
review of the efficacy of using CO2 challenges to induce spontaneous PAs in PD patients 
(without asthma) reported that the vast majority of studies used a standardized protocol of one 
vital capacity inhalation of 35% of CO2 (12). Experimental studies have also shown that PD 
patients are more sensitive to 35% CO2 inhalation than healthy subjects and those with other 
psychiatric disorders (e.g., generalized anxiety disorder and depression) (14, 15) pointing to the 
specificity of this challenge. We are aware of only one study to date that used 35% CO2 challenge 
to induce PAs in patients with a history of respiratory disorders (i.e., asthma and bronchitis), but 
who did not currently have a respiratory disorder (16). Though this study found no association 
between PD and increased subjective distress after the panic challenge, it did not measure any 
physiological (i.e., respiratory) responses, which limits its contribution. It also suffered from 
additional methodological weaknesses: participants with current respiratory disorders were 
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excluded, which limits its generalizability to patients with current asthma diagnoses; and patients 
were included based on self-reports of previous histories of respiratory disorders, which may be 
unreliable, non-specific, and introduces the potential for recall bias, particularly among anxious 
individuals who may over-report asthma (17).  
To address these limitations and more comprehensively assess the link between PD and 
asthma, the present study evaluated the impact of PD and PAs on bronchoconstriction, subjective 
distress, and physiological responses, in patients with documented asthma. It was hypothesized 
that asthmatics with PD who had a PA (PD/PA) in response to one vital capacity inhalation of 
35% CO2, would be more likely to exhibit 1) worse objective airway obstruction, 2) worse 
subjective distress, 3) greater cardiovascular activation, and 4) higher respiratory responses, 
compared to asthmatics without PD who did not have a PA (noPD/noPA).  
 
METHODS 
Participants 
Patients with physician-diagnosed asthma were recruited between September 2011 to 
December 2013 from a prospective database of adult asthma and chronic obstructive pulmonary 
disease patients (RESP - REgistre de données en Santé Pulmonaire). Patients were eligible for the 
study if they had an asthma diagnosis confirmed by evidence of a positive methacholine 
challenge test (MCT) (18) performed in our laboratory prior to the experimentation, were aged 18 
to 70 years old, and could speak English or French. Patients were excluded if they were current 
smokers, had any significant medical conditions that were more serious than asthma (e.g., chronic 
obstructive pulmonary disease), and displayed cognitive or language deficit that would have 
impaired providing informed consent. Patients in the PD/PA group had to meet Diagnostic and 
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Statistical Manual of Mental Disorders, 4th edition, text revised (DSM-IV-TR) criteria for a 
primary psychiatric diagnosis of PD (19) and had to have a positive PA response to the CO2 
challenge (see details in the Measures section); patients in the control group could not meet any 
DSM-IV-TR criteria for any current or past Axis I psychiatric disorder and could not have a PA 
response to the CO2 challenge. For those in the PD/PA group, they were excluded if they met 
criteria for a current Axis I psychiatric disorder that was more severe than PD (e.g., 
schizophrenia, major depression), which was determined by the ADIS-IV (other anxiety or mood 
disorder) and/or self-reported or chart evidence of current diagnoses or medication use 
(psychoses). 
Given the above criteria, a total of 94 individuals were eligible to participate in this study 
(see flow chart of patient inclusion in Figure 1). Of those, 57 declined to participate, which 
resulted in a sample of 37 patients (39% participation rate). Twelve patients were excluded from 
the analyses based on their response to the CO2 challenge (i.e., PD patients who didn’t have a PA 
(n = 3) and no-PD patients who did have a PA (n = 9)), yielding a final sample of 25 patients (15 
PD/PA and 10 noPD/noPA). Written consent was obtained from all participants and the Ethics 
Committee of the Hôpital du Sacré-Coeur de Montréal approved this project (#2003-10-198; 
2010-95).  
 
Study design and procedure 
This quasi-experimental study was part of a larger research protocol assessing bronchial 
responsiveness to a MCT and CO2 panic challenge in asthma patients with and without PD, and 
some aspects of the design have been previously described (20). As part of a larger study, we 
demonstrated that asthma patients with PD who underwent a MCT experienced higher levels of 
subjective distress, but not greater airway responsiveness (bronchoconstriction) than patients 
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without PD, suggesting that the observed increased morbidity in asthma patients with PD is more 
likely due to a catastrophization of bodily symptoms rather than more severe asthma. For both 
studies, eligible patients were contacted by phone by a trained clinical research assistant to 
undergo the Anxiety Disorders Interview Schedule for DSM-IV (ADIS-IV) to assess psychiatric 
disorders. Those who consented presented in the laboratory and completed a screening interview, 
which included demographic information, as well as medical and asthma history (including the 
Asthma Control Questionnaire [ACQ]). 
On their testing day of the panic challenge study, patients were informed that they would 
breathe in one vital capacity inhalation of 35% CO2 (balanced with 65% oxygen). Patients were 
told what symptoms they might experience (including shortness of breath and mild dizziness), 
but that these symptoms, if they occurred, would be temporary (lasting only a few moments) and 
harmless. In order to minimize anticipatory anxiety, they were not explicitly told they might 
experience a “panic attack”, which is consistent with our previous work (21). Further, patients 
were told that they would inhale 35% CO2 or compressed atmospheric air, but would not know 
which they would receive since the gas mixture was randomly selected in a double-blind fashion 
(though all patients received CO2).  
Upon presentation to the laboratory, patients were seated in a comfortable chair and were 
fitted with a mask that was connected to a gas analyzer (Jaeger Oxycon Pro, Carefusion, 
Germany), which in turn was connected online to a computer. For the inhalation of the gas 
mixture, patients were asked to exhale as fully as possible, then take one vital capacity inhalation 
of the gas, hold it for 4 seconds, and then breathe normally. Serial spirometry assessments 
(Spirobank G spirometer, Medical International Research, Inc., Italy) were conducted before and 
for 20 minutes after the inhalation at two minute intervals. Each time, FEV1 was measured twice. 
For the purposes of this study, only the FEV1 measured right before and right after the inhalation 
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were analyzed. A CO2-induced asthma exacerbation was defined as having a ≥10% drop in their 
best (i.e., highest) FEV1 post challenge, because this drop has been reported to be the lower limit 
of clinical significance (22, 23). Respiratory responses were assessed by tidal volume [VT], 
respiratory rate [RR], CO2 production [VCO2], oxygen uptake [VO2] and minute ventilation 
[VE]), which were continuously recorded by the gas analyzer (24). Breath-by-breath recordings 
of respiratory variables were averaged each 5 seconds and then overall averages per group were 
analyzed pre and post gas inhalation. In order to evaluate the proximal effect of the CO2 
inhalation, only the 3 minute period post inhalation was analyzed, which represents the duration 
range of the PA including the administration of subjective distress questionnaires. Cardiovascular 
activation was assessed by heart rate [HR], systolic and diastolic blood pressure [SBP/DBP]) 
(Datascope Accutorr Plus, New Jersey, USA), which were recorded every two minutes. After the 
gas inhalation, there was a recovery period of 20 minutes. Dyspnea (Borg Scale), subjective 
distress (Subjective Distress Visual Analogue Scale [SD-VAS]) and PA assessments (Panic 
Symptom Scale [PSS]) were administered by a trained PhD student in clinical psychology before 
and after the inhalation and prior to spirometry assessment.  
 
MEASURES 
Baseline measures 
Anxiety Disorders Interview Schedule for DSM-IV (ADIS-IV)  
The ADIS-IV (25) is a semi-structured interview typically used to confirm the diagnosis 
of several psychiatric disorders described in the DSM-IV, including mood and anxiety disorders. 
The ADIS-IV was used to determine group psychiatric status. The ADIS-IV has demonstrated 
good inter-rater reliability (k ≥ 0.81) for PD (26, 27).  
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 Asthma Control Questionnaire (ACQ) 
 The ACQ (28) is a 7-item self-report questionnaire that is designed to measure asthma 
control levels by assessing asthma symptoms, activity limitations, and bronchodilator use in the 
past week. An example item is: “In general, during the past week, how limited were you in your 
daily activities because of your asthma?”. Patients rank each item on a 7-point scale (0 = good 
control, 6 = poor control), where higher scores indicate worse control. Finally, the lab technician 
completed the question on spirometry results assessing predicted FEV1.  
 
Experimental measures 
 Panic Symptom Scale (PSS)  
 The PSS (29) is a 13-item questionnaire that was administered as a structured interview 
by a trained PhD student in clinical psychology to assess panic symptomatology. This 
questionnaire, derived from the PA criteria listed in the DSM-III (which has not changed in the 
DSM-5), allows the patient to rank each panic symptom and its intensity on a 5-point Likert-like 
scale (0 = absent to 4 = extremely severe) and the total score indicates the number of symptoms 
(max = 13), as well as the intensity (max = 65) of the PA. A PA in response to the CO2 challenge 
was considered present when a participant endorsed the fear item on the PSS, plus at least 3 other 
items, at the end of the CO2 challenge (6). 
 
Borg Scale  
The Borg Scale (30) is a 12-point self-report scale designed to measure perceived 
breathlessness and is constructed to allow the patient to rate beyond 10, indicating maximal 
intensity. In the field of respiratory diseases, the Borg scale has shown good reliability and 
validity in adult populations (31).  
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 Subjective Distress Visual Analogue Scale (SD-VAS)  
 The SD-VAS (32) is a widely used self-report questionnaire that measures a large variety 
of subjective characteristics. Patients were asked to rate their agreement to 3 statements on their 
level of anxiety, discomfort, and worry, by slashing a continuous horizontal line from 0 (not at 
all) to 100 (extremely). The SD-VAS total score was calculated by measuring the distance 
between the left side of the line to the level rated by the patient, where higher scores represent 
higher intensity. The SD-VAS has shown good reliability and validity (32).    
 
Statistical analyses 
To assess baseline differences between groups in sociodemographic, medical, asthma, and 
psychological characteristics, general linear models (GLM) were used, with partial eta squares 
used as effect sizes (η2). A similar two-group GLM was used to evaluate our first hypothesis, the 
relationship between PD and PA status and bronchoconstriction. In order to test for significant 
main or interaction effects of group and time on subjective distress, and respiratory and 
physiological responses, a series of two-group (PD/PA and noPD/noPA) x two-time (baseline and 
post-CO2) repeated measures mixed model regressions were used to evaluate our second and 
third hypotheses. Age, sex, and provocative concentration of methacholine (PC20: a measure of 
bronchial responsiveness and proxy for asthma severity) were included as a-priori covariates in 
all the analyses, as per the CONSORT and Psychosomatic Medicine guidelines, due to their 
established influences on the main outcome variables (33, 34). F2 was used as a measure of effect 
size per previous work (35). Significance was set at .05 and data analyses were performed using 
SAS v9.4 (SAS Institute, Cary NC). 
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RESULTS 
Sample characteristics 
A total of 25 adult asthma patients were included in the present study. The mean age of 
the sample was 45 years (SD = 15), 84% (n = 21) were female, and 52% (n = 13) were 
cohabitating with a partner. Patients had a mean of 15 years of education (SD = 3), and 80% (n = 
20) were employed. They were on average overweight (mean measured body mass index [BMI] 
kg/m2: M = 27.7, SD = 5.7), and 48% (n = 12) were past smokers. Patients had a mean FEV1 % 
predicted of 97, forced vital capacity (FVC) of 106, and a FEV1/FVC of 83. On average, 
participants had asthma for 20 years (SD = 14) and were prescribed an average daily dose of 
inhaled corticosteroid (ICS) of 590 µg fluticasone equivalent (SD = 529). The mean score on the 
ACQ was 1.03 (SD = 0.89), denoting moderately poorly controlled asthma (28). 
 Table 1 shows the sociodemographic, clinical, asthma-related, and psychological 
characteristics of the participants as a function of PD and PA diagnosis. Participants in the 
PD/PA group had a diagnosis of asthma for a significantly longer period of time in comparison to 
those in the noPD/noPA group. There were no other significant differences between groups.  
 
Association between PD and PA status and objective airway obstruction 
Adjusted analyses showed no main effects of group (mean % [SD]: PD/PA = 93 [2], 
noPD/noPA = 88 [2], F = 2.19, p = .156), a trend for an effect of time (F = 3.06, p = .093), and no 
group by time interaction (F = 0.35, p = .558, f2 = 0.01), indicating that both groups had similar 
FEV1 and there was a similar trend for FEV1 changes in response to CO2 across both groups. 
When measuring the association between PD and PA status and bronchial response, both groups 
had a similar number of participants that experienced a ≥10% drop in their FEV1 post challenge 
(% participants [n]: PD/PA = 27 [4]; noPD/noPA = 10 [1], F = 0.94, p = .344, partial η2 = 0.04), 
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as well as similar overall FEV1 drops (mean % drop of FEV1 [SD]: PD = 8 [8]; No PD = 5 [4], F 
= 0.48, p = .479, partial η2 =0.023), indicating that having a PA did not have a statistically 
significant effect on bronchoconstriction.  
 
Association between PD and PA status and subjective distress 
Table 2 shows the results of the adjusted subjective distress analyses. There was a 
significant difference between groups for all variables, showing that PD/PA patients had more 
panic symptoms and worse anxiety, discomfort, worry, and dyspnea compared to noPD/noPA 
patients, regardless of time. Adjusted analyses also revealed that, across both groups, the panic 
challenge resulted in increased panic symptoms and worse anxiety, discomfort, worry, and 
dyspnea. Interaction effects were also found for several subjective distress variables, which 
illustrated that, in response to the CO2 challenge, PD/PA patients reported an elevated number of 
panic symptoms, worse anxiety, worry, and dyspnea compared to noPD/noPA patients (see 
Figure 2).  
 
Association between PD and PA status and cardiovascular activation 
Table 3 shows the results of the adjusted cardiovascular activation analyses. These 
indicated that there was no significant difference between groups for HR, SBP, and DBP, 
regardless of time. Additionally, only SBP was significantly higher at post-inhalation, regardless 
of group. No significant interaction effects were observed. 
 
Association between PD and PA status and respiratory responses 
Table 4 shows the results of the adjusted respiratory responses analyses. These revealed 
that there were no significant main effects for group or time on respiratory responses. However, 
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three significant interaction effects were found, where PD/PA patients experienced higher levels 
of VCO2, VE, and VT at post-test compared to noPD/noPA patients (see Figure 3).   
As reported in the supplemental material, a different pattern of results was observed when 
patients were assessed as a function of having/not having a PA, regardless of their PD diagnosis, 
where only a main effect of time for VCO2, VE and VT were observed, but no significant 
interaction effect (see supplement).  
 
DISCUSSION 
The present study investigated bronchoconstriction and subjective distress responses to a 
standard panic challenge in a well characterized sample of asthmatics with PD who had a PA, and 
those without PD who did not have a PA. Our hypotheses were partially supported: PD patients 
who had a PA after one vital capacity inhalation of 35% CO2 exhibited elevated levels of 
subjective distress (i.e., symptoms of panic, anxiety, worry, and dyspnea) and increased 
respiratory responses (i.e., VCO2, VE, and VT), but not worse bronchoconstriction nor 
cardiovascular activation (i.e., HR and SBP/DBP) compared to asthmatics without PD who did 
not have a PA. To our knowledge, this is the first study to objectively assess both 
bronchoconstriction and subjective response to a simulated PA in asthmatics with versus without 
PD.  
Contrary to our hypotheses, our results showed no difference in absolute levels of 
bronchoconstriction, as both groups exhibited similar levels of FEV1 after the challenge. Though 
not statistically significant, PD/PA patients were more than twice as likely to experience 
clinically significant bronchoconstriction (defined as a having a ≥10% drop in their FEV1 post 
challenge) than noPD/noPA patients. This suggests that PAs may be associated with an increased 
risk for clinically significant bronchoconstriction under conditions of acute stress, possibly due to 
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a hyperreactive central (autonomic) nervous system that may increase the risk for 
hyperventilation (36, 37). However, this effect did not reach statistical significance in our study, 
possibly due to sample size (low power), and as such is only speculative at this time.  
Consistent with previous reports, this study showed increased subjective and respiratory 
responses following a 35% CO2 challenge for PD/PA patients, even in the absence of any 
objectively measured change in airway obstruction (38), which gives further support to the 
cognitive/affective theory linking PD with worse asthma outcomes (20). Indeed, PAs are often 
characterized by hyperventilation, which may be viewed as a compensatory phenomenon to an 
overly sensitive “suffocation alarm system” in PD patients (39). When a patient's CO2 partial 
pressure rises, the system starts firing at an abnormally low threshold, which may produce a 
cascade of respiratory-related symptoms. These changes could possibly be misinterpreted as life-
threatening asthma symptoms and trigger catastrophic fears about physiological sensations that 
are routinely experienced during a PA, which lead PD patients to overreact to normal 
physiological variations in breathing (40). This, in turn, can lead to a vicious cycle where the 
overreaction to normal bodily sensations stimulates an increase in somatic symptoms, which 
confirms their original catastrophic thought (41). Nonetheless, severe asthma attacks may provide 
legitimate cause for patient concern and be sufficient to produce hypersensitivity to respiratory 
sensations, which then serve as conditioned stimuli of anxiety-induced hyperventilation and panic 
(2, 42, 43).  
From a neural control perspective, PD patients having a PA may have abnormally 
elevated respiratory responses, as seen in the current study (i.e., VT, VE), which indicates that 
breathing regulation may be dysfunctional (44, 45). Although, it seems like the sensation of 
suffocation plays a central role in both disorders, in asthma it could be considered a “true” alarm 
triggered by bodily sensations related to an abnormality of peripheral respiratory mechanisms. 
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Conversely in PD, it has been suggested to be a “false” alarm related to a dysfunctional 
“suffocation alarm system” (39, 46). Interestingly, the supplemental analysis comparing patients 
that had a PA to those who did not have a PA regardless of their PD status demonstrated that the 
pattern of respiratory responses no longer showed any significant interaction effect but only a 
main effect of time for VCO2, VE and VT, reflecting this tendency of hyperventilation to 
rebalance the O2 uptake and CO2 elimination. These additional findings illustrate an adjustment 
to the CO2 challenge (i.e., time effect) without observing any differentiating effects of group, 
which suggests that only PD patients experience abnormally elevated respiratory responses to the 
CO2 compared to participants that would have had a PA regardless of their mental state (see 
supplemental material). This further supports the importance of having PA’s in the context of PD 
rather than just PAs alone.  
Our findings are consistent with other cognitive/affective theory studies demonstrating no 
correlation between subjective distress and objective measures of asthma (47-50), but differ from 
those supporting a psychophysiological pathway suggesting that anxiety and mood disorders are 
associated with increased asthma or cardiovascular symptomatology (51-53). Nonetheless, our 
findings are clinically relevant since hypocapnia induced by hyperventilation, experienced during 
a patient’s daily life, creates cognitive and respiratory symptoms that asthma patients cannot 
control using asthma medication, which could adversely affect their perception of control over 
the management of their disease (54). This could result in over-use of medication (i.e., short-
acting bronchodilators) and increased health service use (7, 8).  
The present study has some limitations that should be considered when interpreting the 
results. First, patients were recruited from a single tertiary care outpatient clinic, which is made 
up of moderate-severe asthma patients, so our study would generalize to a similar population but 
not necessarily asthmatics treated in the community. In addition, the study sample was selective 
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(e.g., exclusion of individuals with PD who are non-panicking) to answer the research questions 
and to obtain a well characterized sample. Second, our sample size was relatively small (n = 25), 
and is possible that a larger sample size may have increased power to detect a significant 
difference because of observed small effect size, especially regarding our findings on 
bronchoconstriction (partial η2 of 0.02 for overall drop in FEV1 post challenge and of 0.04 for 
experienced a ≥10% drop in their FEV1 post challenge). Given the aversive nature of the study 
protocol, getting asthma patients with PD to participate voluntarily to experience a simulated PA 
was a challenge. To address the possibility of selection bias, we performed additional analyses 
(see Supplement) to verify if the pattern of results changed if we looked at the effects of having a 
PA (or not) regardless of PD status and we observed a similar pattern of results. This increases 
our confidence in the generalizability of the findings. Third, it has been suggested that the use of 
CO2 to induce PAs may not be optimal because the concentrations used are higher than 
concentrations present during a “natural” PAs (55) and due to potential bronchodilatory effects of 
CO2 (56). However, CO2 inhalation tends to induce PAs that are milder and end quicker (i.e., 
when the inhalation is finished) than ‘natural’ PAs (57), suggesting that our results represent at 
worst, conservative estimates of the true effect of naturally occurring panic attacks, which remain 
difficult to reproduce experimentally. Further, CO2 has been repeatedly shown to reliably induce 
PAs in similar experimental settings (12, 21, 57, 58). While it is true that CO2 may induce 
hypercapnia, which is associated with bronchodilatation, this tends to be observed in subjects 
with hypercapnia that is stable for at least 10 minutes. In our study, hypercapnia was only 
temporary (seconds to one minute maximum) as subjects inhaled only one vital capacity 
inhalation of a gas mixture containing 35% CO2 (balanced with O2) and then breathed room air. 
Thus, we are confident that exposures in our study were not long enough to induce 
bronchodilation and significantly obscure any changes in bronchoconstriction. However, it would 
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be interesting to replicate our findings with another panicogenic substance. Fourth, one potential 
limitation and an area for future research would be to use other lung function measures (e.g., 
airway resistance, oscillatory resistance) to assess the impact of acute stress on 
bronchoconstriction which are more sensitive than spirometry (59). We chose to measure 
bronchoconstriction using spirometry, because of its clinical relevance and make our results 
accessible and meaningful to clinicians (60) who treat asthma and often struggle with 
differentiating asthma from panic/anxiety. However, it does raise the prospect that spirometry 
may have under-estimated the effect of panic disorder and panic attacks on bronchoconstriction. 
Future work should aim to use more sensitive measures of lung function to address this potential 
limitation. Fifth, the clinical research assistant assessing panic symptoms using the PSS was not 
blind to the psychiatric status of patients and this may have introduced some bias. However, the 
PSS was administered as a structured interview and scoring was done separately by computer. In 
addition, patients were blind to which gas they would get (CO2 or O2, even though they all got 
CO2), which minimizes any potential subjective bias by the clinical research assistant. In 
addition, the ADIS-IV was conducted by a single student, so specific inter-rater reliability 
information is not available for this study. However, it was administered by a trained PhD-level 
graduate student with 3 years of experience that was supervised by an experienced psychologist. 
Finally, we did not assess patients’ perceptions about whether or not they were experiencing a 
panic or asthma attack during the CO2 challenge, which limits the understanding of the impact of 
the cognitive interpretation on the findings. 
Despite these limitations, the present study also has a number of important strengths. 
First, this study makes a novel contribution to the existing literature by being the first, to our 
knowledge, to use a standardized and reliable panic challenge (one vital capacity inhalation of 
35% CO2) to assess bronchoconstriction and subjective responses in a well-characterized sample 
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of objectively diagnosed asthmatics with versus without interview-derived PD. Second, we 
included objective measures of pulmonary function (i.e., FEV1), as well as many other objective 
measures of respiratory and physiological responses, in order to assess specific and generalized 
arousal during a PA. Finally, we used a validated and reliable interview to assess PD and rule out 
any history of psychiatric disorders (i.e., ADIS-IV), and based PA diagnoses on DSM criteria.  
 In conclusion, this study improves our understanding of the role of PAs on objective 
airway obstruction, subjective and respiratory distress, and cardiovascular activation in 
asthmatics with and without PD. Having a PA in reaction to CO2 was associated with elevated 
subjective distress and respiratory responses, but not with bronchoconstriction or cardiovascular 
activation, which suggests that PAs may exacerbate asthma via predominantly cognitive/affective 
mechanisms, though studies with larger samples are needed to replicate and confirm these 
findings. In addition, it would be interesting to conduct another study that uses qualitative 
interviews to deepen our understanding of symptom perception. Clinical trials should be 
considered to assess the impact of treating PD using validated strategies such as cognitive 
behaviour therapy on symptoms, ventilatory and airway obstruction in response to CO2. This 
could help direct treatment resources toward this subgroup of asthma patients who may be at 
greater risk for asthma exacerbation and morbidity as a result of their comorbid psychiatric status.  
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Table 1: Participant sociodemographic, medical, asthma, and psychological characteristics. 
 PD/PA  
(n = 15) 
noPD/noPA 
(n = 10) 
 
F 
 
p η2 
Sociodemographics      
Age (years) 43 ± 15 47 ± 15 0.43 .519 0.02 
Sex (% female) 94 (14) 70 (7) 2.48 .129 0.10 
Ethnicity (% white) 87 (13) 100 (10) 1.42 .246 0.06 
Cohabitating (% yes) 53 (8) 50 (5) 0.02 .877 0.00 
Education (years) 15 ± 3 15 ± 4 0.08 .779 0.00 
Employed (% yes) 87 (13) 70 (7) 1.00 .328 0.04 
Medical and asthma 
characteristics 
     
PC20 levels (geometric M [95%CIs])  0.47 [0.15 - 
1.46] 
0.48 [0.12 - 
1.95] 
0.00 .961 0.00 
Measured BMI (kg/m2) 27 ± 5 29 ± 6 0.75 .396 0.03 
Past smoker (%) 47 (7) 50 (5) 0.02 .877 0.00 
Emergency visits (% in the last year) 13 (2) 0 (0) 1.42 .246 0.06 
Asthma duration (years) 25 ± 18 13 ± 7 4.52 .045* 0.16 
FEV1 (% predicted) 99 ± 12 94 ± 16 0.86 .363 0.04 
FVC (% predicted) 110 ± 12 101 ± 11 3.97 .058 0.15 
FEV1 / FVC (% predicted) 90 ± 2 93 ± 3 0.07 .795 0.00 
ACQ score 0.97 ± 0.83 1.11 ± 1.02 0.15 .702 0.01 
Medication use      
ICS dose (µg) 605.38 ± 
608.11 
428.57 ± 
228.47 
1.03 .320 0.00 
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Combined LABA (%) 47 (7) 50 (5) 0.02 .877 0.00 
Beta-2 short action (%) 80 (12) 90 (9) 0.42 .524 0.02 
Any antidepressants (%) 47 (7) 10 (1) 4.00 .057 0.15 
Any anxiolytics (%) 20 (3) 0 (0) 2.30 .143 0.09 
Note. Data are presented as M ± SD or percent (n). ACQ = Asthma Control Questionnaire; BMI 
= Body Mass Index; FEV1 = Forced Expiratory Volume in one second; FVC = Forced Vital 
Capacity; ICS = Inhaled Corticosteroids; noPD/noPA = No Panic Disorder and No Panic Attack 
group; PC20 = Provocative Concentration of methacholine; PD/PA = Panic Disorder and Panic 
Attack group. 
Statistical test used: General linear models.  
* Significant difference between the groups set at 0.05
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Table 2: Effect of PD and PA status and time on subjective distress following a 35% CO2 challenge.  
Note. noPD/noPA = No Panic Disorder and No Panic Attack group; PD/PA = Panic Disorder and Panic Attack group; PSS = Panic 
Symptom Scale; SD-VAS = Subjective Distress Visual Analogue Scale.  
 M ± SD Main effects Interaction effect 
 PD/PA noPD/noPA PD and PA 
status 
Time PD and PA x time 
 Pre-test Post-test Pre-test Post-test F p F p F p F2 for 
interaction 
PSS - Number of panic 
symptoms 
1.65 ± 
0.44 
8.58 ± 0.60 0.82 ± 
0.31 
3.62 ± 
0.52 
33.32 <.001* 63.01 <.001* 18.10 <.001* 0.33 
PSS - Total score†  5.80 ± 
0.71 
7.16 ± 1.47 7.01 ± 
0.78 
5.84 ± 
0.61 
0.25 .624 0.27 .612 2.11 .161 0.03 
SD-VAS – Anxiety 8.66 ± 
3.61 
58.88 ± 
6.49 
1.12 ± 
1.62 
9.22 ± 
3.44 
43.42 <.001* 24.63 <.001* 21.93 <.001* 0.35 
SD-VAS - Discomfort 9.35 ± 
4.50 
62.43 ± 
8.45 
2.77 ± 
3.65 
35.67 ± 
7.34 
7.91 .011* 48.99 <.001* 2.93 .101 0.06 
SD-VAS – Worry 6.50 ± 
2.51 
55.14 ± 
7.00 
2.16 ± 
1.94 
7.96 ± 
2.23 
44.32 <.001* 22.90 <.001* 26.31 <.001* 0.41 
Borg scale 1.20 ± 
0.51 
5.91 ± 0.89 0.93 ± 
0.39 
3.08 ± 
0.95 
7.71 .012* 29.25 <.001* 4.68 .042* 0.09 
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† Adjusted for the number of panic symptoms on the PSS. 
Statistical test used: Repeated measures mixed model regressions. 
* Significant difference between the groups set at 0.05 
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Table 3: Effect of PD and PA status and time on cardiovascular responses following a 35% CO2 challenge. 
Note. DBP = Diastolic Blood Pressure; HR = Heart Rate; PD = Panic Disorder; noPD/noPA = No Panic Disorder and No Panic Attack 
group; PD/PA = Panic Disorder and Panic Attack group; SBP = Systolic Blood Pressure.  
Statistical test used: Repeated measures mixed model regressions. 
* Significant difference between the groups set at 0.05 
 M ± SD Main effects Interaction effect 
PD/PA noPD/noPA PD and PA 
status 
Time PD and PA x time 
Pre-test Post-test Pre-test Post-test F p F p F p F2 for 
interaction 
HR 76.56 ± 3.61 79.52 ± 3.35 70.50 ± 3.58 72.40 ± 3.32 4.31 .052 3.16 .091 0.11 .739 0.003 
SBP 120.33 ± 3.08 129.41 ± 3.81 121.14 ± 3.42 128.96 ± 4.70 0.00 .975 9.48 .006* 0.04 .837 0.001 
DBP 74.76 ± 2.22 80.70 ± 2.25 74.71 ± 1.37 76.65 ± 2.72 0.72 .408 5.75 .026 1.02 .324 0.03 
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Table 4: Effect of PD and PA status and time on respiratory responses following a 35% CO2 challenge. 
 
Note. noPD/noPA = No Panic Disorder and No Panic Attack group; PD/PA = Panic Disorder and Panic Attack group; RR = 
Respiratory rate (breaths/min); VCO2 = Carbon Dioxide production (ml/kg/min); VE = Minute Ventilation (L/min); VO2 = Oxygen 
Uptake (ml/kg/min); VT = Tidal Volume (L).  
Statistical test used: Repeated measures mixed model regressions. 
* Significant difference between the groups set at 0.05
 Main effects Interaction effect 
 PD and PA status Time PD and PA x time 
 F P F p F p F2 for interaction 
VCO2 0.71 .398 1.21 .271 5.89 .015* 0.05 
VO2 0.03 .865 0.68 .401 3.03 .082 0.06 
VE 3.43 .064 1.45 .228 4.48 .034* 0.07 
VT 0.09 .765 1.41 .235 4.62 .032* 0.06 
RR 4.55 .033 0.79 .374 0.45 .502 0.06 
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Figure 1: Flow chart of patient screening, eligibility, and participation. 
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Figure 2: Interaction effect of PD and PA status and time following a 35% CO2 challenge on A) 
the number of panic symptoms of PSS, B) anxiety on the VAS, C) worry on the SD-VAS, and D) 
Borg Scale. 
  
Note. noPD/noPA (dashed line) = No Panic Disorder and No Panic Attack group; PD/PA (solid 
line) = Panic Disorder and Panic Attack group; PSS = Panic Symptom Scale, SD-VAS = 
Subjective Distress Visual Analogue Scale. Presented as Means ± S.E 
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Figure 3: Interaction effect of PD and PA status and time following a 35% CO2 challenge on A) 
VCO2, B) VE, and C) VT. 
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Note. noPD/noPA = No Panic Disorder and No Panic Attack group; PD/PA = Panic Disorder and 
Panic Attack group; VCO2 = Carbon Dioxide production; VE = Minute Ventilation; VT = Tidal 
Volume.  
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